BUZZ-Innovent Biologics rises as regulator approves co's product for cancer treatment
** Shares of Innovent Biologics Inc 1801.HK rise 3.3% to HK$31, on course to snap two consecutive session of decline
** Stock on track for the biggest one-day jump since Dec. 9, 2024; among top 10 gainers in healthcare index .HSCIH, which is up 0.8%
** Innovent says new drug application of limertinib - the third-generation epidermal growth factor receptor tyrosine kinase inhibitor, has received approval by National Medical Products Administration of China (NMPA) for treatment of lung cancer
** Hang Seng Commerce & Industry Index .HSNC and Hang Seng Index .HSI boht slip 0.1%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available